Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma

Clinical trial NCT07712757 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07712757
Sponsor: Nuvation Bio Inc.
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation Astrocytoma IDH Mutant Grade 2 Oligodendroglioma Oligodendroglioma IDH-mutant and 1p/19q-codeleted IDH-mutant Gliomas

Start date: 2027-03-01
Primary completion: 2029-05-01
Enrollment: 140

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.